In the brand-new tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says. These days, doctors are viewing the two drugs as “more similar than different,” Leerink Partners analyst Ami Fadia wrote in a Monday note to clients. According to a survey conducted by the firm, physicians see the Teva drug snapping up 45% of peak market share, compared with Ingrezza’s 55%; that’s an i...
FIERCEPHARMA
READ MORE
|
It is well-known in the medical field that the pig brain shares certain physiological and anatomical similarities with the human brain. So similar are the two that researchers at the University of Georgia's Regenerative Bioscience Center have developed the first U.S. pig model for stroke treatments, which will provide essential preclinical data and speed the drug discovery process....
READ MORE
|
Switching describes a physician’s decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs....
READ MORE
|
US authorities have charged six companies of price fixing in the US, India, and Australia. Drugmakers Mylan, Heritage Pharmaceuticals, Teva Pharmaceutical USA and Citron Pharma are named in the lawsuit alongside India’s Aurobindo Pharma and Australia’s Mayne Pharmaceuticals....
ZME SCIENCE
READ MORE
|
A new implantable device has been approved for use in Europe to help treat acid reflux disease. The IM RefluxStop device from Implantica, a company based in Zug, Switzerland, is designed to avoid some of the limitations of current minimally invasive reconstructive acid reflux procedures, such as difficulty swallowing, burping, and vomiting. The company reports that in the latest comparison of its technology against Nissen fundoplication, the most common type of GERD procedure, “the new met...
REFLUXSTOP
READ MORE
|
Increasingly fraught Sino-American relations are beginning to have a real impact on the health sector, after it emerged that the health networking startup PatientsLikeMe is being forced to find a buyer after the Trump administration ordered its Chinese majority owner to divest its stake. According to CNBC, the divestiture is happening following a review by the Committee on Foreign Investment in the United States (CFIUS), which is aggressively cracking down on Chinese investment in the country. I...
PHARMAPHORUM
READ MORE
|